GlaxoSmithKline PLC (GSK)

16.680
-0.080(-0.48%)
  • Volume:
    49,321
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    16.660 - 16.900
  • Type:Equity
  • Market:Germany
  • ISIN:GB0009252882
  • WKN:940561

GSK Overview

Prev. Close
16.76
Day's Range
16.66-16.9
Revenue
38.35B
Open
16.84
52 wk Range
13.9-18.2
EPS
-
Volume
49,321
Market Cap
82.84B
Dividend (Yield)
0.89
(5.31%)
Average Volume (3m)
73,641
P/E Ratio
16.33
Beta
-
1-Year Change
6.72%
Shares Outstanding
5,004,943,939
Next Earnings Date
-
What is your sentiment on Glaxo Smith Kline PLC?
or
Market is currently closed. Voting is open during market hours.

Glaxo Smith Kline PLC News

Glaxo Smith Kline PLC Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellNeutralSell
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellNeutralNeutral

Glaxo Smith Kline PLC Company Profile

Glaxo Smith Kline PLC Company Profile

Employees
94066

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Read More
  • 1399.60p described as a good Divi stock but where's the potential capital growth... will wait for sub 1200.00p
    0
    • The current CEO seems to have lost confidence, time for a change to inject new life into the company
      5
      • the news from today remarked that investors present applauded during the event.
        0
      • the question is what percentage of GSK shareholders attended, most big investors gont go to such events
        0
      • while true, until we know who attended it's hard to gauge lost confidence. at the start of the day pre share holder day, the share price was 20p down, that swung to 40p up at one point, hardly signals negativity
        0
    • Seems to me that a stake is being built, especially from the area of £13.25 upwards. We already have the "activist" investment fund but another buyer is around. Seems similar to whats been happening in BT shares over the last few weeks. Stay long and collect dividends on the way. Hopefully
      1
      • what will happen when the split happens in 2022?!
        0
    • MINAYULSK
      0
      • There is absolutely value at its 12m lows 1190.00 so I'm waiting for any bad news and will buy in the dips.... Are THEY PAYING A Dividend???
        3
        • Yes, 23p per share last time round in April
          0
        • I believe the next dividend, may 20th, is 19p.
          0
        • thanks Paul , Simon.
          0
      • Broken above descending channel. Very likely to be start of a bull run.
        0
        • One of the most undervalued stock in ftse100
          0
          • The market hates that the dividend is being reduced next year to 50p
            0
          • Huge debt
            0
          • Manju SinghManageable debt like Abbvie
            0
        • Always comes back up. Will be £13 + before long.
          2
          • We are just hitting a major trendline at 1257 today, it's a very good sign if it clears it.
            2
            • Yes, she's heading back up for sure.
              2
          • This is an old boring dinasaur.
            7
            • Nothing wrong with a few old boring dinasaurs in your portfolio
              3
            • Hans Ontitsright up your pseudonym street
              0
          • I think this gives a nice dividend
            2
            • Now the tech uber bubble in growth/momentum stocks is deflating, this looks excellent value with decent dividends to move that money into.
              1
          • 1150 is coming next week
            14
            • Strong Sterling is causing the fall. There has to be a limit to Sterling's rise so I can't see this falling much further.
              1
              • Took your advice and got a few. £12 is a bargain in theory
                2
            • Mi too :-(
              1
              • Drop more worse compare the time covid hit market
                0
            • The drop make me nervous
              0
              • If it drops, buy more! Cheap
                2
            • Value Will be in 11.50 mark soon.
              4
              • Great stock to accumulate, Glaxo could spring a big surprise in the foreseeable future as they are rumored to be working on a Covid treatment (not vaccine) which could put them in a different league altogether
                4
                • Whats that exactly?
                  1
                • Will go down
                  1
              • I think it's good time to buy.
                5
                • definitely @ 1223, can't lose.
                  1
              • Not surprisingly, as a result of managements' NR regarding future dividend cuts, long term income funds and investors moving to better, more stable income prospects which are plentiful currently.
                0
                • when is the next results?
                  1
                  • c. 04 Feb 2022 for next annual results.  Next quarterly update will be end of April this year.
                    1
                  • thank you. do you think we are going to see an upward trend soon?
                    2
                  • ah Zak Not at all.  The company will split into two within the next two years, and the dividend will halve as a result.  Best to leave this and come back in three years.
                    1
                • Pharma are slow moving stocks in the first place, if at all u need to buy pharma stocks then go for AZN, even just do a swop at present and you will not regret
                  4
                  • I just keep buying more as it drops for my ISA. No brainer. Drop doesnt really make any fundamental sense. Great long term hold.
                    4
                    • they are looking very cheap now so frustrating good numbers solid business making profit really can't understand why this has dropped so far
                      2
                      • No hype. Its boring dividend company. Things will change, but it takes time.
                        2
                      • You need to dig deeper into the company
                        0
                    • 1150 is coming, anything above is too risky
                      2
                      • Bases on what?
                        2
                      • Dobromir YordanovIf you have done your research properly you would know why
                        1
                    • I do not expect the selling to continue much, only those who bought before 2009ish etc. would sell on a profit (not taking dividend into account).... Beyond that it makes no sense to me why anyone who bought in recent history would be selling now!
                      3
                      • Yes but where does it find support now
                        0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.